Goal of TESAR
Colorectal cancer is the third most common cancer and second cause of cancer related death in the Netherlands with 13,500 new cases each year. Approximately 34 percent of these are cancers of the rectum. Rectal cancer surgery is accompanied with high morbidity and long term poor functional outcome. Screening programs have shown to result in a shift towards more early staged cancers.
Patients with early rectal cancer can potentially benefit significantly from rectal preserving therapy resulting in significantly less morbidity and better function and quality of life compared to radical surgery. For the earliest stage cancers, local excision is sufficient when the risk of lymph node disease and subsequent recurrence is <5%. However, the majority of early cancers are associated with an intermediate risk of lymph node involvement (5-20%) suggesting that local excision alone is not sufficient. However, completion radical surgery, which is currently standard of care, could be a substantial overtreatment for this group of patients.
The aim of this study is to determine the oncological safety, treatment related morbidity, and the functional outcome of rectal preserving therapy for early rectal cancer; local excision followed by adjuvant chemo-radiotherapy is compared to local excision followed by completion radical resection of intermediate risk early rectal cancer